Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2012, 802796

A Randomised, Double-Blind, Placebo-Controlled Trial With Vitamin D3 in MS: Subgroup Analysis of Patients With Baseline Disease Activity Despite Interferon Treatment

Affiliations

A Randomised, Double-Blind, Placebo-Controlled Trial With Vitamin D3 in MS: Subgroup Analysis of Patients With Baseline Disease Activity Despite Interferon Treatment

J Aivo et al. Mult Scler Int.

Abstract

We present a subgroup analysis of the first double-blind, placebo-controlled, randomised trial with vitamin D3 in MS. In the overall study population, there were 34 patients in the vitamin D arm and 32 patients in the placebo arm. All the patients were using interferon-β-1b (IFNB) therapy. The subgroup consisted of 15 patients in the vitamin D arm and 15 patients in the placebo arm, who had either at least one relapse during the year preceding the study or enhancing T1 lesions at the baseline MRI scan. We measured the total number of MRI T1 enhancing lesions, the number of new/enlarging T2 lesions and T2 lesion volume (BOD) (mm(3)), EDSS (Expanded Disability Status Scale), annual relapse Rate (ARR), timed 25-foot walk (T25FW), and timed 10-foot tandem walk (TT10W) at baseline and at 12 months in the vitamin D-treated and in the placebo-treated patients. There was a statistically significant reduction in the number of T1 enhancing lesions, a smaller T2 lesion volume growth and less new/enlarging T2 brain MRI lesions in the vitamin D3-treated than in the placebo-treated subgroup patients. The MRI results were slightly more pronounced in the subgroup than in the overall study population.

Figures

Figure 1
Figure 1
Study flow chart.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Soilu-Hänninen M, Aivo J, Lindstrom BM, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurol Neurosurg Psychiatry. 2012;83(5):565–571. - PubMed
    1. Banwell B, Bar-Or A, Arnold DL, et al. Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. The Lancet Neurology. 2011;10(5):436–445. - PubMed
    1. Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Sclerosis. 2005;11(3):266–271. - PubMed
    1. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, Mononen I. A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2008;79(2):152–157. - PubMed
    1. Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Multiple Sclerosis. 2008;14(9):1220–1224. - PubMed

LinkOut - more resources

Feedback